Elevance Health (ELV) Q3 2025: Medicaid Margin to Drop 125bps, Resetting Baseline for 2026
Elevance Health faces a strategically significant Medicaid margin reset, with management flagging at least a 125 basis point decline for 2026, anchoring a new baseline for future recovery. The quarter was characterized by disciplined execution and targeted investments, yet persistent Medicaid headwinds and policy uncertainty force a cautious approach to guidance. Investors are now watching for how swiftly Elevance can restore earnings growth while navigating regulatory, reimbursement, and risk pool volatility.
Summary
- Medicaid Margin Reset: Management signals a substantial margin decline in Medicaid for 2026, establishing a new earnings floor.
- Strategic Capital Deployment: Investments in AI, platform integration, and Carillon expansion are prioritized over near-term expense leverage.
- Recovery Path Focus: 2027 is positioned as a return to balanced growth, contingent on cost control and policy clarity.
Business Overview
Elevance Health is a diversified health benefits and services company operating across three major segments: Commercial (employer-sponsored and ACA plans), Government (Medicaid and Medicare Advantage), and Carelon (pharmacy, behavioral health, and specialty services). Revenue is primarily generated through insurance premiums and fee-based services, with Carillon, the company’s care delivery and pharmacy platform, driving an increasing share of external revenue. Medicaid and Medicare Advantage are significant contributors, but both are exposed to regulatory and reimbursement cycles.
Performance Analysis
Elevance delivered 12% year-over-year revenue growth in Q3, fueled by higher premium yields, recent acquisitions, and Medicare Advantage membership gains. However, Medicaid membership declined due to ongoing redeterminations, and the segment’s operating margin turned modestly negative, a trend expected to deteriorate further into 2026. Benefit expense ratio aligned with expectations, but cost pressures from elevated acuity and utilization, particularly in Medicaid and ACA, were not fully offset by rate increases.
Carillon continued to outperform, with RX revenue up 20% and services growing over 50% year-over-year, underscoring the strategic value of Elevance’s integrated platform. Commercial business showed stable trends, with high retention and expansion in fee-based relationships, while ACA margins remain pressured by risk pool deterioration and policy uncertainty.
- Medicaid Margin Compression: Full-year Medicaid margin is now expected to be slightly negative, with at least a 125 basis point drop forecast for 2026.
- Carillon Growth Offsets: Robust pharmacy and services expansion, but headwinds from health benefits membership losses will weigh on results next year.
- Investment-Driven Cost Structure: Several hundred million dollars in targeted investments are planned for technology, care delivery, and operational quality, impacting near-term expense leverage.
Elevance’s financial posture remains cautious, with capital deployment shifting toward integration, digital innovation, and shareholder returns, rather than further acquisitions.
Executive Commentary
"We are reaffirming 2025 adjusted EPS of approximately $30 and continue to view $27 as the appropriate earnings baseline, excluding $3 of discrete, non-recurring items. As we plan for 2026, our posture is prudent and practical, and we're approaching next year with discipline and focus."
Gail Boudreau, President and CEO
"Our current outlook assumes our Medicaid operating margin will decline by at least 125 basis points year over year. The critical factors underpinning this input include the ongoing misalignment of rates and acuity, elevated utilization trends, and funding and eligibility changes in certain states."
Mark Kay, Chief Financial Officer
Strategic Positioning
1. Medicaid Margin Reset and Restructuring
Elevance is proactively resetting expectations for Medicaid, projecting a margin decline of at least 125 basis points in 2026. This reflects persistent misalignment between rates and rising acuity, as well as elevated utilization. Management is working closely with states on rate adequacy and program changes, but acknowledges that 2026 will be a trough year, with sequential improvement expected in 2027 as rates catch up and operational initiatives take hold.
2. Carillon Platform Expansion and Diversification
Carillon, Elevance’s care delivery and pharmacy platform, continues to post strong double-digit growth in both pharmacy and services. The company is migrating specialty pharmacy scripts to its BioPlus platform and integrating acquired assets like Kroger Specialty Pharmacy, aiming to diversify revenue beyond Elevance’s own membership base and reduce exposure to core benefit segment volatility.
3. AI and Digital Transformation as Cost and Experience Levers
Elevance is investing heavily in AI and automation, embedding digital tools across clinical workflows, member engagement, and provider operations. AI-enabled virtual assistants and HealthOS platform are already reducing administrative burden and driving measurable improvements in cost management and member experience, positioning Elevance for future margin leverage.
4. Prudent Capital Allocation and Integration Focus
After several years of acquisition-driven expansion, capital deployment is shifting toward integrating existing assets, scaling Carillon capabilities, and targeted share repurchases. Management is clear that durable, long-term performance is prioritized over near-term expense reduction, with investments front-loaded to position the business for a more balanced earnings growth profile in 2027 and beyond.
5. Disciplined Product and Market Participation
Elevance is exiting unprofitable Medicare Advantage plans and service areas, focusing on geographies and products aligned with its value-based care strategy. In ACA, the company is prepared for multiple policy scenarios regarding enhanced premium subsidies, with product design and pricing reflecting higher observed acuity and risk pool instability.
Key Considerations
This quarter marks a strategic inflection, with Elevance setting a new baseline for Medicaid profitability and signaling a shift in resource allocation toward integration, technology, and sustainable growth levers. The company’s ability to execute on operational and policy fronts will determine the speed and durability of recovery.
Key Considerations:
- Medicaid Margin Reset: 2026 will be a trough year for Medicaid profitability, with recovery dependent on rate catch-up and operational initiatives.
- Carillon External Growth: Diversification of pharmacy and services revenue is accelerating, but headwinds from internal membership losses must be managed.
- AI as Strategic Enabler: Investments in AI and digital tools are already yielding efficiency and experience gains, supporting long-term margin expansion.
- Policy and Regulatory Uncertainty: ACA subsidy expiration and Medicaid program changes introduce significant risk to membership and revenue stability for 2026.
- Capital Allocation Discipline: Focus is on integration, technology, and share buybacks, rather than new acquisitions, to drive future value creation.
Risks
Elevance faces material risks from persistent Medicaid cost pressures, delayed rate alignment, and policy-driven membership volatility in both Medicaid and ACA segments. Regulatory changes, state-level budget constraints, and the uncertain fate of enhanced ACA subsidies could drive further margin compression or revenue contraction. Execution risk in integrating Carillon assets and scaling digital initiatives also remains, especially as investments are front-loaded and near-term leverage is deprioritized.
Forward Outlook
For Q4 2025, Elevance guided to:
- Full-year adjusted EPS of approximately $30, with $27 as the recurring baseline excluding discrete items.
- Medicaid operating margin expected to be modestly negative for 2025, with at least a 125 basis point decline in 2026.
For full-year 2026, management will provide a formal EPS range in January, with key variables including:
- Medicaid rate updates and state program changes
- ACA subsidy policy outcomes and Medicare AEP results
Management highlighted that 2026 is expected to be the low point for Medicaid margins, with sequential improvement in 2027 as cost control, rate alignment, and operational initiatives mature.
Takeaways
Investors should recognize this quarter as a strategic reset for Elevance, with management transparently communicating the Medicaid margin trough and outlining a credible path to recovery.
- Margin Inflection: The 125 basis point Medicaid margin decline anchors 2026 as a reset year, not the start of a prolonged deterioration, with management focused on operational and policy levers for recovery.
- Platform Diversification: Carillon’s growth and external revenue momentum demonstrate the value of Elevance’s integrated model, but internal membership losses remain a near-term headwind.
- Watch for 2027 Rebound: The pivot to integration, AI, and disciplined product participation is designed to restore balanced earnings growth, contingent on successful execution and policy clarity in the coming quarters.
Conclusion
Elevance Health’s Q3 2025 results reflect disciplined execution amid industry headwinds, but the company’s forward posture is defined by a Medicaid margin reset and a shift to long-term, investment-driven positioning. The next twelve months will test Elevance’s ability to navigate policy risk, cost trends, and integration, with 2027 positioned as the inflection for renewed growth.
Industry Read-Through
Elevance’s Medicaid outlook and margin reset are a cautionary signal for the broader managed care sector, as persistent risk pool deterioration, delayed rate alignment, and state budget pressures are not unique to ELV. Carillon’s external growth highlights the strategic value of diversified platforms that can offset core insurance volatility, a model increasingly relevant for peers. AI and digital transformation are emerging as critical cost and experience levers, and the sector’s winners will be those who can scale these initiatives to drive both affordability and operational leverage. Policy risk remains elevated, particularly in ACA and Medicaid, and sector participants should be prepared for continued volatility in membership and margins through 2026.